Essen Speciality (ESFL)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 70.85% aligns owner-managers with minority shareholders
• ROCE of 11.50% shows capital deployment is not negative, though mediocre
• Current price of ₹136.50 is near the lower end of the 52-week range of ₹108.30–₹439.00
• Latest quarter sales of ₹41 Cr give the company a meaningful operating scale relative to its ₹334 Cr market cap
• Small dividend yield of 0.74% indicates some existing shareholder return policy

Concerns

• Profit growth of -120.48% and latest quarterly net loss of ₹2 Cr show severe earnings deterioration
• Sales growth of -12.69% indicates a shrinking top line
• Piotroski F-score of 3/9 signals weak overall financial health
• P/E of 370.93 is unsupportable when earnings are near zero or negative
• No book value, ROE, or debt/equity data prevents any realistic margin-of-safety calculation

AI Analysis

At a glance, Essen Speciality fails the first test I apply: does the business earn attractive returns on capital while showing predictable growth? Sales are down 12.69%, profit growth is minus 120.48%, and the latest quarter shows a net loss of ₹2 Cr on sales of ₹41 Cr. A Piotroski F-score of 3/9 reinforces the picture of a company under financial stress, not one compounding wealth. The reported P/E of 370.93 looks absurd, but in Graham's terms it is not even a real P/E; it is a market cap of ₹334 Cr sitting on near-zero or falling earnings. With book value and ROE listed as N/A, I cannot calculate the margin of safety that Graham demanded. I also cannot trust the balance sheet without debt/equity data. The stock has fallen from ₹439 to ₹136.50, down nearly 69%, which shows how quickly the market can re-rate a business with weak fundamentals. The positive points: promoters own 70.85%, aligning their interests with minority holders, and ROCE is 11.50%, moderate but not exceptional. The dividend yield of 0.74% is small comfort. This looks like a cyclical or struggling speciality plastics player in a difficult phase. I would want to see sales stabilizing, positive quarterly profits, and clearer evidence of a durable moat before putting any money here. In Buffett's language, it is a cigar butt at best, and without a clean financial statement, I would rather pass. Price alone does not make a bargain; a wonderful business at a fair price is better than a weak business at a low price, and here even the price is not demonstrably low.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer